Search

The article presents information on a study which reports that thioredoxin inhibitor AW464 hammers tumor growth under hypoxic conditions. AW464 is a novel benzothiazole substituted quinol compound active against colon, renal and certain breast cancer cell lines. NCI COMPARE analysis indicates possible interaction with thioredoxin/thioredoxin reductase, which is upregulated under hypoxia. Through activity on HIF1alpha, VEGF levels are regulated and angiogenesis controlled. A thioredoxin inhibitor could therefore exhibit enhanced hypoxic toxicity and indirect antiangiogenic effects. In vitro experiments were performed on colorectal and breast cancer cell lines under both normoxic and hypoxic conditions and results compared against those obtained with normal cell lines, fibroblasts and keratinocytes. The study was conducted by researcher A. Mukherjee and colleagues, and published in the "British Journal of Cancer."

The article sites a study analyzing that thioredoxin inhibitor AW464 hammers tumor growth under hypoxic conditions. The study was conducted by the researcher A. Mukherjee and colleagues at the University of Nottingham, City Hospital. Antiangiogenic effects were studied using both large and microvessel cells. Indirect antiangiogenic effects were studied via enzyme-linked immunosorbent assay. AW464 exerts antiproliferative effects on tumor cell lines as well as endothelial cells with an IC[50] of approximately 0.5 mcM. Mukherjee and colleagues published their study in "British Journal of Cancer."